Role of Corticosteroids in Myocarditis
Corticosteroids are contraindicated in typical viral myocarditis but are immediately indicated for immune checkpoint inhibitor (ICI) myocarditis, giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis, and inflammatory myopathy-related myocarditis. 1
When Corticosteroids Are HARMFUL and Must Be Avoided
The European Society of Cardiology assigns a Class III (harm) recommendation against corticosteroids in viral pericarditis/myocarditis due to risk of viral reactivation. 1
- NSAIDs and corticosteroids increase inflammation and mortality in isolated myocarditis without pericardial involvement. 1
- Corticosteroids do not reduce mortality in viral myocarditis (RR 0.93,95% CI 0.70-1.24) and can perpetuate viral infections rather than resolving inflammation. 1, 2, 3
- Anti-inflammatory therapy with steroids alone (without IVIG) is not beneficial in pediatric viral myocarditis. 4
When Corticosteroids Are INDICATED
Immune Checkpoint Inhibitor (ICI) Myocarditis
Emergent high-dose corticosteroids (1 mg/kg methylprednisolone IV) must be initiated immediately in suspected or confirmed ICI myocarditis. 5, 1, 6
Dosing regimen for ICI myocarditis (NCCN guidelines, strong evidence): 6
- Pulse phase: Methylprednisolone 1 g IV daily for 3–5 consecutive days
- Continuation: Maintain steroids until cardiac function (LVEF) returns to baseline
- Taper: Gradual dose reduction over 4–6 weeks once function normalizes
- Escalation: If no clinical improvement within 24 hours, add second-line immunosuppressant (antithymocyte globulin, infliximab, IVIG, or mycophenolate)
Critical pitfall: Any delay in starting steroids markedly worsens outcomes; treatment must begin at suspicion, not confirmation. 6
Giant Cell Myocarditis, Cardiac Sarcoidosis, and Eosinophilic Myocarditis
Immunosuppression with corticosteroids is indicated for these specific histologic subtypes. 1, 7
Inflammatory Myopathy-Related Myocarditis
High-dose IV methylprednisolone (10–20 mg/kg) for 1–5 days, followed by oral prednisone 0.5–1 mg/kg/day for 2–4 weeks in combination with a steroid-sparing agent (methotrexate, azathioprine, or mycophenolate mofetil). 6
COVID-19 Myocarditis
Use corticosteroids if the patient has both myocarditis AND COVID-19 pneumonia requiring supplemental oxygen. 1, 8
Intravenous corticosteroids may be considered in suspected/confirmed COVID-19 myocarditis with hemodynamic instability or multisystem inflammatory syndrome in adults (MIS-A). 1
- A systematic review of 18 cases showed 72% of patients with COVID-19 myocarditis who received corticosteroids experienced major clinical improvements. 8
- The most commonly used agent was methylprednisolone (89%), administered intravenously for 1–14 days. 8
Pediatric Myocarditis with MIS-C
In multisystem inflammatory syndrome in children (MIS-C) with myocarditis, use low-to-moderate dose glucocorticoids (1-2 mg/kg/day) as adjunctive therapy with IVIG in patients with shock and/or organ-threatening disease. 4
For pediatric patients with juvenile dermatomyositis and cardiac involvement, use prednisone 2 mg/kg/day (maximum 60 mg/day) after IV pulse therapy. 6
Diagnostic Workup Required Before Steroid Decision
Mandatory Immediate Evaluation
Immediate cardiology consultation, ICU-level monitoring, continuous telemetry, and 12-lead ECG are mandatory. 6
Biomarker assessment: 6
- Serum creatine kinase and troponin (troponin I preferred when skeletal-muscle disease is present)
- BNP/NT-proBNP (levels > 500 pg/mL signal significant cardiac stress)
- ESR, CRP, and white blood cell count
Cardiac MRI is recommended when feasible to confirm myocardial inflammation. 1, 6, 4
Red-Flag Findings Requiring Immediate High-Dose Steroids
Troponin ≥ 1.5 ng/mL confers a ~4-fold increased risk of major adverse cardiac events (MACE). 6
Other red flags: 6
- New dyspnea, palpitations, chest pain, or syncope in a patient with underlying myositis
- Hemodynamic instability or cardiogenic shock
- Bulbar or respiratory failure (dysphagia, dysarthria, severe dyspnea)
Special Consideration for ICI Myocarditis
Troponin may remain normal for 2–4 hours after symptom onset and can take up to 12 hours to become abnormal; serial measurements at 3-hour and 6-hour intervals are required to reliably exclude necrosis. 6
A single normal troponin cannot exclude ICI myocarditis; serial troponin testing over a 6–10 hour window is mandatory. 6
For possible but unconfirmed ICI myocarditis, the decision to start steroids should be made with cardiology input; delays in treatment markedly worsen outcomes. 5, 6
Recommended Treatment Approach for Viral Myocarditis (Instead of Steroids)
Guideline-directed medical therapy for heart failure: 1, 4
- ACE inhibitors/ARBs
- Beta-blockers (if hemodynamically stable)
- Aldosterone antagonists
- Diuretics as appropriate
Activity restriction for 3–6 months is mandatory—sustained aerobic exercise during acute viral myocarditis increases mortality and sudden death risk. 1
Mechanical circulatory support (ECMO, ventricular assist devices) if cardiogenic shock develops despite optimal medical management. 1, 4
For pediatric viral myocarditis, first-tier immunomodulatory treatment is IVIG at 2 g/kg based on ideal body weight, not corticosteroids alone. 4
Monitoring and Common Pitfalls
Continue steroids until objective cardiac function returns to baseline; then initiate the 4–6-week taper. 6
Avoid premature taper—early dose reduction can precipitate disease flare. 6
Recognize co-occurring immune toxicities: myositis or myasthenia gravis accompany > 40% of ICI-myocarditis cases and 10% of fatal cases; their presence mandates aggressive steroid therapy. 6
Normal cardiac enzymes do not exclude myocarditis; comprehensive evaluation (imaging, biomarkers, clinical picture) remains essential. 6
Permanent ICI discontinuation is required for any grade 3 or 4 cardiovascular immune-related adverse event. 6